←
Alex Federation779 posts
Alex Federation avatar

Alex Federation

@afederation

Co-founder, CEO of Talus Bio structure-free discovery for frontier drugs

◷ Joined December 2008▧ 59 Photos and videos
Alex Federation avatar
Alex Federation@afederation·Jul 31

Do we even need to fold proteins at all to find drugs? Or do we just do that to satisfy our 3D brains? Meet Ptarmigan-1 🧵 - Structure-free drug discovery - 5000x less compute than co-folding - Finds known and cryptic pockets - Actually works on poorly structured targets

Post attachment
Alex Federation avatar
Alex Federation@afederation·Nov 5

Just got back from the AI Drug Discovery conference in Boston, and my big takeaway is the rise in the number of AI drug discovery models, how few have lab data behind them, and how much everyone wants to see that data. Most are benchmarked on the same leaky public datasets, so it’s hard to tell which ones actually work. We have our own lab, so the experiment is part of our loop, but third party lab validation also should play a big part, @adaptyvbio is a great example for protein design What should look like in the small molecule space? What targets? I go back and forth on this. An easy target (a kinase or something) is cheap to test, but is probably just memorization at this point. A hard target (a TF, something without an obvious pocket) would be convincing if it worked. It also usually requires assay dev, and a negative result tells you very little. And what's the bar? Is it biochemical potency? Selectivity across the family? The proteome? Engagement in cells? Inhibiting protein function? More questions than answers at this point, but we'll keep sharing how we're thinking about this as we get more data

Post attachment
Jay Bradner, M.D. avatar
⟳ Alex Federation retweeted
Jay Bradner, M.D.@jaybradner·Nov 3

Jon Clardy was a brilliant scholar and a wonderful man, beloved uniformly in chemistry and chemical biology from Boston to Brazil. My sincerest condolences to those who were lucky to know him well, as mentees and close friends. RIP, Jon, just cannot believe you are gone.

Jon Clardy: 1943-2026 One of the most impactful, creative, and (quietly) irreverent practitioners of chemical biology. Transformed how we think about nature's chemicals: their structures, their role in biology. Loved him -- he had tremendous influence on my thinking.

Post attachment
Alex Federation avatar
Alex Federation@afederation·Oct 27

One cool example on a former "undruggable" target (KRAS) -- Ptarmigan-1 ranked known KRAS G12C compounds in the order of their development generations without ever being trained on affinity, this ranking required the mutation to be present. Across 337 drug-like complexes, the top-scoring residue sat within 5 Å of the ligand 92% of the time, from sequence and chemistry alone

Alex Federation avatar
Alex Federation@afederation·Oct 27

ptarmigan.app/ How it works -- We encode specific protein residues and their context alongside compounds into a shared highly-dimensional latent space. Since we're not folding a new protein and new compound with every experiment, we embed a library once and reuse it, unlocking massive speed.

Alex Federation avatar
Alex Federation@afederation·Oct 27

We opened the API and MCP for our structure-free drug discovery model (Ptarmigan-1) today. With that, we're also increasing usage limits by 1,000x In my first week of grad school I sat through a lecture on ‘undruggable’ targets, which ended up being a frustrating (but motivational) moment, and I've worked the last 15 trying to help remove this term from the trade. Ptarmigan-1 is a first step to let AI target these proteins, powered by native-cell data where these targets are at home. With the API/MCP, you (or your agent) can now rank up to 10M compounds against a protein using only its sequence, with no 3D structure predict where it will bind. That's ~10 GPU-years of co-folding

Post attachment
Ash Jogalekar avatar
⟳ Alex Federation retweeted
Ash Jogalekar@curiouswavefn·Oct 27

Another thing: AlphaFold is like a tiny, tiny, slice of all of biology. It's a great technical accomplishment, but it applies to static, well-formed structures (not intrinsically disordered proteins - roughly 30% of the entire proteome), and still cannot handle dynamic multimers well. It also depended on having enough data: 200,000 structures in the PDB and counting. Saying that AlphaFold works, therefore we could "solve" biology with enough compute, is like saying that because we can predict the shape of every component in a car, we can predict everything the car will do on the road. And saying that compute or reasoning can somehow magically compensate for data is a religious belief.

If you had an exponential amount of compute you could solve simulate biology exactly and wouldn't need to run any experiments. Some of you will think "of course, but that's an unrealistic assumption" and others will think "no, you need experiments even with that much compute. That's just How It's Done". You would of course need evaluations once you have a solution, but you don't in principle need experiments to find it: Experiments are a way to save compute, dating from a time when it was much more expensive. And I think the presentation is exponential but real systems aren't irreducibly exponential. AlphaFold worked, after all.

Alex Federation avatar
Alex Federation@afederation·Oct 21

Unlocking hard drug targets means searching massive chemical spaces Since opening a structure-free discovery model 2 weeks ago (Ptarmigan-1), users have already tested 2M+ compounds for free This would have taken years of compute with co-folding models

0:11
Alex Federation avatar
Alex Federation@afederation·Oct 1

Today we’re opening our structure-free AI drug discovery model for all to use! Ptarmigan-1 predicts which small molecules bind a protein, and where, without building a 3D protein structure. It learns from multiple kinds of data, including measurements of proteins at work inside living human cells. This is the culmination of a long and winding path to get here In my first week of grad school, I sat in a lecture hall where generations of chemists had trained and Nobel Prizes hung on display. One of the most accomplished chemists in the world introduced us to the word “undruggable,” describing targets that so many had given up on. I remember sitting there feeling so indignant. Of course all targets are impossible to drug until the right technology lets you drug it. Thankfully I found my people in @jaybradner's lab, where the T-shirts said “nothing is undruggable”, and got to work We focused on gene regulators there, proteins that control which genes turn on and off and can drive cancer. Most are poorly structured, making them difficult targets for traditional tech that focus on a well-defined binding pocket. Gene regulators are not the only disordered proteins though. Roughly 40% of the human proteome has significant disorder, and these targets remain out of reach while discovery for structured proteins gets faster every year. With Ptarmigan-1, we’re giving researchers a way to search for molecules against these targets without first having to solve their structure. I’m grateful to the team and supporters that brought us here. Now we get to see what the community does with it. Try it and tell us what you think. Link below.

2:26
Alex Federation avatar
Alex Federation@afederation·Sep 24

Well in my hands the bio filters have a 100% false positive rate, but I'm no statistician 🤷‍♂️

Today, we'll resume charging for requests our safeguards block before Claude responds. This only applies in categories with low false positive rates: biology, distillation attacks, and frontier LLM development. We've seen some coordinated attacks on our systems in recent weeks, and this is one layer of defense. In recent testing, 99.7% of accounts using Claude Code, Claude​.ai, or Cowork did not hit any of these newly "billable blocks." The classifiers behind the blocks we’re resuming charging for today are tuned to have a <0.1% false positive rate. We know that's not 0%, and we're going to keep improving them so they interrupt your work less often. If you think a request has been blocked incorrectly, please report it with /feedback in Claude Code. platform.claude.com/docs/en/…

Alex Federation avatar
Alex Federation@afederation·Sep 22

A molecule for every target that needs one

We’re hearing two kinds of voices on the potential of AI to cure all disease: One says AI will cure everything, but without a concrete path to get there. The other says biology is too complex to ever tame, but underestimates the power of the tools that will unlock the full potential of frontier intelligence. At Manifold Bio, we see a path and we’re already building it: a high-throughput interface into living system biology. Millions of protein designs, measured directly in vivo, to learn how molecules behave in the body and ultimately predict what they’ll do before they reach a patient. Today we share mBER-2, the latest iteration of our AI protein design model that is a core piece of this mission.

Gleb Kuznetsov avatar
⟳ Alex Federation retweeted
Gleb Kuznetsov@glebkuz·Sep 22

We’re hearing two kinds of voices on the potential of AI to cure all disease: One says AI will cure everything, but without a concrete path to get there. The other says biology is too complex to ever tame, but underestimates the power of the tools that will unlock the full potential of frontier intelligence. At Manifold Bio, we see a path and we’re already building it: a high-throughput interface into living system biology. Millions of protein designs, measured directly in vivo, to learn how molecules behave in the body and ultimately predict what they’ll do before they reach a patient. Today we share mBER-2, the latest iteration of our AI protein design model that is a core piece of this mission.

Today, we’re announcing mBER-2, our latest AI protein design system, and sharing a bit of how we use it to explore biology in vivo at scale. For a long time, we’ve been working on what I think of as “frontier problems” in medicine and biology. We know a lot about the targets involved in disease, but there is still an enormous amount of biology we haven’t explored, and potential uses for that biology we haven’t discovered. One of those problems is drug delivery. There are thousands of potential targets, and most receptors remain unexplored as routes for delivering medicines. We want to understand which ones we can use, where they can take a drug, and what kinds of molecules make that possible. Ultimately, we need to test these molecules in vivo to understand what they actually do. We’ve spent the last six years building measurement technologies that let us generate millions of measurements in living systems. mBER-2 is an AI protein design system built for that scale of in vivo measurement. Our goal is to generate binders across the full range of targets we care about, while systematically exploring the possible binding sites on each one. It’s not just what you bind, but where and how you bind that determines whether a molecule performs it's function. mBER-2 lets us probe those differences at massive scale. We’re also sharing a look at some of our in vivo data. We’ve designed more than 50 million molecules across over 4,000 targets, and screened millions of molecules in living systems. By probing hundreds of receptors, we’ve found new pathways for delivering genetic medicines into fat that outperform industry benchmarks by a large margin. This is just the beginning. We call the space of all bindable sites across proteomes the EpiTome. As we explore it, we’re building the data to connect AI design, receptor binding, and what a molecule actually does in a living organism. Much like the idea of a virtual cell, we envision a Virtual Organism that helps us design medicines with specific properties in mind. The foundation is our own in vivo data, connecting molecular design to outcomes measured in living systems. The endgame is to use AI to explore more biology, measure what happens, and use what we learn to design better medicines. Every round should deepen our understanding of biology and improve our ability to build molecules that do what we need them to do.